Metagenomi Therapeutics, Inc.
MGX- Exchange
- Nasdaq
- Industry
- Biological Products, (No Diagnostic Substances)
- SEC CIK
- 0001785279
In the last 90 days, Metagenomi Therapeutics, Inc. insiders filed 1 open-market purchase and 3 sales; 43 institutions reported holding it in 13F filings for Q2 2026, worth $7.45M in total; no superinvestor holds it.
Superinvestors holding MGX, Q2 2026
No superinvestor reported holding MGX in Q2 2026.
Moves by quarter
Superinvestors that opened, added to, trimmed or sold out of MGX each quarter, comparing shares with the quarter before. A superinvestor that didn't file for a quarter isn't listed, and isn't counted as selling.
Q2 2025
0 superinvestors holding at quarter end
- Sold out
- HHLR Advisors (Hillhouse)
Q1 2025
1 superinvestor holding at quarter end
- Reduced
- HHLR Advisors (Hillhouse) (−80.6%)
Q1 2024
1 superinvestor holding at quarter end